CHINA SHINEWY P To Go Ex-Dividend On April 29th, 2024 With 1.17823 USD Dividend Per Share
April 3rd - $CHINA SHINEWY P(CSWYY.US)$ is trading ex-dividend on April 29th, 2024. Shareholders of record on April 30th, 2024 will receive 1.17823 USD dividend per share on June 3rd, 2024. The ex
moomoo NewsApr 2 19:40 ET
Shenwei Pharmaceutical is happy to report that annual profit attributable to shareholders is expected to increase by about 30% to 36% year over year
Shenwei Pharmaceutical (02877) announced that the profit attributable to the company's owners for the year ended December 31, 2023 is expected to increase by about 30% to 36% compared to the same period last year (2022: about RMB 723 million). The expected increase in profit attributable to company owners this year is mainly due to an increase in the Group's overall sales revenue of about 14% compared to last year and a decrease of about 2 to 3 percent in the ratio of sales and distribution costs to turnover compared to last year.
新浪港股Mar 7 04:00 ET
CCB International: Maintaining Shenwei Pharmaceutical's “Outperforming Market” Rating, Target Price Reduced to HK$9.5
According to a research report released by CCB International, the target price of Shenwei Pharmaceutical (02877) was lowered by 13.6%, from HK$11 to HK$9.5, and its earnings forecast for FY2024 was RMB 1.249, reflecting the worsening sentiment of volume procurement (VBP) of traditional Chinese medicine formula granules on the Chinese pharmaceutical industry listed in Hong Kong, but it still maintained an “outperforming market” rating. The dividend rate was 7% from 2023, benefiting from strong cash flow. According to the report, the average price of traditional Chinese medicine formula granules GPO/VBP (Group Purchasing Organization/Volume Procurement) fell 50% year over year. Despite this, the third in 2023
新浪港股Nov 12, 2023 23:14 ET
CHINA SHINEWY P To Go Ex-Dividend On September 11th, 2023 With 0.30073 USD Dividend Per Share
August 31st - $CHINA SHINEWY P(CSWYY.US)$ is trading ex-dividend on September 11th, 2023. Shareholders of record on September 12th, 2023 will receive 0.30073 USD dividend per share on October 16th
moomoo NewsAug 30, 2023 19:40 ET
Shenwei Pharmaceutical announced interim results, net profit of 491 million yuan, up 48.4% year-on-year
Shenwei Pharmaceutical (02877) announced its 2023 interim results, with a turnover of 2,399 billion yuan (RMB, same below), up 32.1% year on year, another record high in mid-term sales performance; net profit of 491 million yuan, up 48.4% year on year; basic profit of 65 points per share, and proposed an interim dividend of 11 points per share.
新浪港股Aug 30, 2023 00:40 ET
Shenwei Pharmaceutical will pay a second interim dividend of 0.11 yuan per share on September 29
Shenwei Pharmaceutical (02877) announced that the company will pay a second interim dividend of RMB 0.11 per share on September 29, 2023.
新浪港股Aug 30, 2023 00:16 ET
Shenwei Pharmaceutical's Fa Yingxi expects profit attributable to mid-term shareholders to increase by about 45% to 50% year-on-year
Shenwei Pharmaceutical (02877) announced that the profit due to company owners for the six-month period ending June 30, 2023 is expected to increase by about 45% to 50% over the same period last year (same period in 2022: RMB 331 million). According to reports, the increase in profit attributable to company owners during this period is mainly due to an increase in the Group's overall sales revenue of about 32% and an increase in gross margin and net profit margin compared to the same period last year. Sales of all dosage forms increased during this period. Among them, sales of injectable products and traditional Chinese medicine formula granular products increased by about 37% and 34%, respectively.
新浪港股Aug 3, 2023 01:06 ET
Promote the standardization construction from a high starting point to meet the market opportunity
Original title: promote standardization construction from a high starting point to meet market opportunities Source: Shijiazhuang Daily-Chief reporter Fan Yulei, correspondent Hou Qingbin, November 1, the national pilot work of traditional Chinese medicine formula granules was officially completed, and market access was fully liberalized. In order to speed up the entry into the national market, Shenwei Pharmaceutical Group, the leading enterprise of modern traditional Chinese medicine in our city, on the one hand, speeds up the filing of national standards for formula granules, on the other hand, by expanding the production capacity of traditional Chinese medicine formula granules, stepping up the expansion of sales team and other measures, actively welcome the coming "spring" of the great development of traditional Chinese medicine formula granules.
媒體滾動Nov 3, 2021 09:00 ET
No Data
No Data